Search

Xenon Pharmaceuticals Inc

Lezárt

SzektorEgészségügy

35.92 0.39

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

35.76

Maximum

36.54

Fő mutatók

By Trading Economics

Bevétel

-8.4M

-111M

Egy részvényre jutó nyereség

-1.11

Munkavállalók

358

EBITDA

420K

-111M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+95.29% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 2.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

-2.4B

3.6B

Előző nyitás

35.53

Előző zárás

35.92

Hangulat hírek alapján

By Acuity

50%

50%

133 / 340 Rangsor szerint Healthcare

Xenon Pharmaceuticals Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. okt. 6. 20:02 UTC

Xenon Pharmaceuticals Inc shares fell sharply, continuing a downward trend with unusually high volume and remaining below the 20-day moving average.

2026. okt. 5. 20:06 UTC

News

Xenon Pharmaceuticals Inc shares are declining, continuing a trend from Friday's close, despite an earlier rebound from a session low.

2026. okt. 2. 21:01 UTC

News

Xenon Pharmaceuticals Inc announced equity inducement grants to new employees, with after-market trading showing a slight gain since Friday's close.

2026. okt. 1. 23:55 UTC

Xenon Pharmaceuticals Inc declined in after-market trading, moving lower since Thursday's close and remaining significantly below its 20-day moving average.

2026. szept. 30. 20:07 UTC

Xenon Pharmaceuticals Inc. shares fell, closing lower than Tuesday's close after an early drop, remaining below its 20-day moving average.

2026. szept. 29. 20:01 UTC

Xenon Pharmaceuticals Inc is advancing today with increased trading volume, recovering from earlier losses to reach a peak in late morning.

2026. szept. 28. 23:55 UTC

Xenon Pharmaceuticals Inc. is trading lower in after-hours, shifting from a slight gain to a more substantial loss since Monday's close, remaining below its 20-day moving average.

2026. szept. 25. 20:01 UTC

Xenon Pharmaceuticals Inc shares fell sharply, pressured by broader biotechnology sector weakness, and are nearly 3% below Thursday's close.

2026. szept. 24. 23:35 UTC

Xenon Pharmaceuticals Inc is trading modestly higher in after-market hours, reflecting a cumulative gain since Thursday's close despite a significant decline over the past month.

2026. szept. 23. 20:02 UTC

News

Xenon Pharmaceuticals Inc. shares fell sharply amid an investigation by Schall, Brown & Schwartz LLP for potential securities law violations related to its clinical trials.

2026. szept. 22. 20:07 UTC

News

Xenon Pharmaceuticals Inc is advancing slightly higher, following its announcement to present at the TD Cowen Summit on September 23, 2026.

2026. szept. 21. 20:06 UTC

News
Social Media

Xenon Pharmaceuticals shares fell amid analyst target cuts, with Baird lowering its target to $90 and Needham reducing it to $60, while enrollment in trials is paused.

2026. szept. 18. 23:06 UTC

Xenon Pharmaceuticals Inc is up in after-market trading, buoyed by broader market trends despite ongoing concerns over industrial sector weakness and rising Treasury yields.

2026. szept. 17. 23:01 UTC

Social Media
News

Xenon Pharmaceuticals submits a New Drug Application for azetukalner but pauses new patient enrollment in other studies, leading to a significant decline in after-hours trading.

2026. szept. 16. 20:10 UTC

Xenon Pharmaceuticals Inc is advancing modestly in Wednesday's market session, despite earlier pulling back from a session high amid a broadly lower market.

2026. szept. 15. 20:02 UTC

Xenon Pharmaceuticals shares are lower amid broader market declines linked to a significant drop in the NY Empire State Manufacturing Index for September.

2026. szept. 14. 22:01 UTC

Xenon Pharmaceuticals Inc shares are higher in after-market trading, recovering from recent declines despite remaining below the 20-day moving average. No specific news was identified.

2026. szept. 11. 20:08 UTC

Xenon Pharmaceuticals Inc shares are lower, marking six consecutive sessions of declines. Broader market sentiment may be affected by a rise in the Consumer Price Index.

2026. szept. 9. 20:07 UTC

Xenon Pharmaceuticals Inc. shares are lower today, marking the fourth consecutive session of declines, with no specific news identified for the drop.

2026. szept. 8. 20:41 UTC

Xenon Pharmaceuticals Inc shares are lower in after-market hours amid a broader market decline, with no specific company news identified for the drop.

2026. szept. 4. 23:40 UTC

Xenon Pharmaceuticals Inc shares are higher in after-market hours, despite no specific company news, amid broader macroeconomic influences.

2026. szept. 1. 20:09 UTC

News

Xenon Pharmaceuticals shares are lower as negative sentiment follows an insider sale of 7,068 shares by Chief Medical Officer Kenney Christopher John.

2026. aug. 31. 23:31 UTC

Xenon Pharmaceuticals Inc shares are higher in after-market trading, reflecting an upward move since Monday's close amid broader market expectations for interest rate hikes.

2026. aug. 28. 20:02 UTC

News

Xenon Pharmaceuticals shares are lower as the company presented Phase 3 data on azetukalner at the European Epilepsy Congress, amid market volatility.

2026. aug. 27. 20:02 UTC

Social Media
Event
News

Xenon Pharmaceuticals will present Phase 3 X-TOLE2 trial data at an epilepsy meeting. Shares are lower despite recent announcements regarding upcoming presentations.

2026. aug. 26. 21:51 UTC

News

Xenon Pharmaceuticals will present data on azetukalner at the European Epilepsy Congress in September 2026, contributing to shares moving higher in after-market hours.

2026. aug. 24. 19:56 UTC

Xenon Pharmaceuticals Inc shares are lower today, reflecting ongoing market weakness. The stock is near the lower end of its one-month range.

2026. aug. 21. 23:51 UTC

Xenon Pharmaceuticals shares are lower in after-market trading, reflecting challenges in maintaining upward momentum and positioning below the 20-day moving average.

2026. aug. 20. 22:51 UTC

Shares of Xenon Pharmaceuticals are lower in after-market trading, continuing a trend of three consecutive daily declines and trading below the 20-day moving average.

2026. aug. 19. 23:01 UTC

Xenon Pharmaceuticals Inc. is higher in after-market trading, rebounding from an initial dip and reflecting strength despite no specific news to explain the movement.

Társak összehasonlítása

Árváltozás

Xenon Pharmaceuticals Inc Előrejelzés

Célár

By TipRanks

95.29% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 71.417 USD  95.29%

Magas 90 USD

Alacsony 46 USD

16 Wall Street elemző 12 hónapos célárain alapulva a(z)Xenon Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

16 ratings

15

Vétel

1

Tartás

0

Eladás

Hangulat

By Acuity

133 / 340 Rangsor szerint Egészségügy

Hangulat hírek alapján

Neutral

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag alatti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.